首页 > 市场调查报告书 > 医疗设备

导管

市场调查报告书

商品编码

1634217

全球射频消融设备市场 - 2025 - 2033

Global Radiofrequency Ablation Devices Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球射频消融设备市场规模达56.3亿美元，预计2033年将达到135.4亿美元，2025-2033年预测期间复合年增长率为10.7%。

射频消融（RFA）是一种微创医疗手术，透过高频交流电产生热量，然后用它来消除或消融体内的某些组织。此手术广泛应用于各种医学专业，包括介入放射学和心臟病学，特别有助于治疗肿瘤、心律不整和慢性疼痛。该方法包括将一根细针或导管引入所需位置，并施加射频辐射以引起局部加热。这种热会破坏异常组织，削弱或消除其功能。

RFA 具有广泛的应用。在肿瘤学中，它被用来消灭肝臟、肺和肾臟等器官中的恶性肿瘤。在心臟病学中，射频消融用于解决导致心律不整的心臟电路故障。它也用于疼痛管理，以破坏导致慢性疼痛疾病（包括关节炎和下背痛）的神经讯号。 RFA 的多功能性使其成为现代医学的重要工具，为患者提供侵入性最小的优质医疗替代方案。

市场动态：

驱动程式和限制

对射频消融设备的需求不断增加

对射频消融设备的需求不断增长预计将成为全球射频消融设备市场成长的重要因素。由于慢性病盛行率上升、技术进步、对微创外科手术的日益偏好以及最近的推出和批准，对体内给药装置的需求不断增加。

随着癌症、心血管疾病和慢性疼痛等慢性疾病变得越来越普遍，医疗保健提供者正在寻找有效的治疗替代方案，以减少患者的痛苦并缩短復原时间。例如，根据美国心臟学会基金会的数据，高收缩压对年龄标准化 CVD 伤残调整生命年 (DALY) 的贡献最大，全世界每 10 万人中有 2,564.9 人患有高收缩压。

RFA 是一种诱人的解决方案，因为它能够精确定位异常组织，同时保持邻近的健康结构。此功能在肿瘤学中特别有用，RFA 用于治疗实体肿瘤，为可能不适合标准手术的患者提供了可行的选择。该市场也受到技术进步的推动，这些进步提高了这些设备在各种医疗环境中的功效、安全性和可用性。随着医疗保健格局的变化，RFA 技术的进步使这些设备更容易使用和有效地治疗各种疾病，包括慢性病和恶性肿瘤，这些疾病在全球范围内变得越来越普遍。 RFA 技术最重要的进步之一是引入多针电极装置。这些方法可以实现更精确的组织定位，使医生能够以更高的精度治疗更大的区域，同时减少对附近健康组织的损害。这种准确性在肿瘤学中至关重要，在保留健康结构的同时正确消融肿瘤细胞的能力对患者的治疗结果有重大影响。

此外，RFA 设备中包含的即时监控功能可以为临床医生在手术过程中提供即时回馈。此功能可更好地控制能量传递过程，确保在整个治疗过程中保持适当的温度，从而提高安全性和有效性。最近推出并批准了射频消融设备。例如，2024 年 10 月，波士顿科学公司宣布用于治疗阵发性心房颤动 (AF) 的具有导航功能的 FARAWAVE NAV 消融导管已获得 FDA 批准，以及新 FARAVIEW 软体的 FDA 510(k) 许可，它将与FARAPULSE 脉衝场消融(PFA) 系统结合使用，为心臟消融手术提供可视化。这些技术仅与波士顿科学公司现有的心臟测绘技术和该公司的最新产品 OPAL HDx 测绘系统相容。

与射频消融装置相关的副作用和併发症

与射频消融设备相关的副作用和併发症等因素预计将阻碍全球射频消融设备市场。 RFA 通常被认为是一种安全且侵入性极小的治疗方法，但它并非没有潜在危险。接受 RFA 的患者可能会出现多种副作用，包括不适、水肿和注射部位附近的过敏。这些症状可能表现为灼热感或麻木，类似于晒伤，并且可能在手术后持续数天甚至数週。这种不适感可能会导致患者不满并不愿意在未来继续接受这种治疗，进而影响整体市场的接受度和成长。此外，儘管不常见，但在 RFA 操作期间或之后可能会出现更严重的问题。注射部位感染、神经和血管损伤以及出血都是可能的併发症。

Radiofrequency ablation (RFA) is a minimally invasive medical procedure that generates heat from high-frequency alternating current and then uses it to eliminate or ablate certain tissues in the body. This procedure is widely used in a variety of medical specialties, including interventional radiology and cardiology, and is especially helpful in treating tumors, cardiac arrhythmias, and chronic pain. The method involves introducing a tiny needle or catheter into the desired location and applying radiofrequency radiation to induce localized heating. This heat causes the destruction of aberrant tissue, diminishing or eliminating its function.

RFA has a wide variety of applications. In oncology, it is used to destroy malignancies in organs like the liver, lungs, and kidneys. In cardiology, RFA is used to address faulty electrical circuits in the heart that cause arrhythmia. It is also used in pain management to disrupt nerve signals that cause chronic pain diseases including arthritis and lower back pain. RFA's versatility makes it an essential instrument in modern medicine, providing patients with superior healthcare alternatives that are minimally intrusive.

Market Dynamics: Drivers & Restraints

Increasing demand for radiofrequency ablation devices

The increasing demand for radiofrequency ablation devices is expected to be a significant factor in the growth of the global radiofrequency ablation devices market. The demand for on-body drug delivery devices is increasing owing to the rising prevalence of chronic diseases, technological advancements, growing preference for minimally invasive surgical procedures, and recent launches and approvals.

As chronic disorders like cancer, cardiovascular disease, and chronic pain become more common, healthcare providers are looking for efficient treatment alternatives that will reduce patient misery and recovery time. For instance, according to the American College of Cardiology Foundation, High systolic blood pressure contributed the most to age-standardized CVD disability-adjusted life years (DALYs), with 2,564.9 per 100,000 people worldwide.

RFA is an enticing solution because it enables precision targeting of aberrant tissues while maintaining adjacent healthy structures. This feature is especially useful in oncology, where RFA is used to treat solid tumors, giving it a viable option for patients who may not be candidates for standard surgery. The market is also driven by technological advancements that improve the efficacy, safety, and usability of these devices in a variety of medical settings. As the healthcare landscape changes, advances in RFA technology make these devices more accessible and effective for treating a wide range of ailments, including chronic diseases and malignancies, which are becoming more common worldwide. One of the most significant advances in RFA technology has been the introduction of multi-needle electrode devices. These methods enable more precise tissue targeting, allowing doctors to treat larger areas with higher accuracy while reducing damage to healthy tissues nearby. This accuracy is critical in oncology, where the ability to properly ablate tumor cells while conserving healthy structures has a substantial impact on patient outcomes.

Furthermore, the inclusion of real-time monitoring capabilities in RFA devices gives clinicians immediate feedback during operations. This feature provides greater control over the energy delivery process, ensuring that the proper temperature is maintained throughout the treatment, improving both safety and effectiveness. There are recent launches and approvals of radiofrequency ablation devices. For instance, in October 2024, Boston Scientific Corporation announced that the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) has received FDA approval, as well as FDA 510(k) clearance for the new FARAVIEW Software, which will be used in conjunction with the FARAPULSE Pulsed Field Ablation (PFA) System to provide visualization for cardiac ablation procedures. These technologies are only compatible with Boston Scientific's existing cardiac mapping technology and the company's newest product, the OPAL HDx Mapping System.

Side effects and complications associated with radiofrequency ablation devices

Factors such as side effects and complications associated with radiofrequency ablation devices are expected to hamper the global radiofrequency ablation devices market. RFA is generally regarded as a safe and minimally intrusive therapy, however, it is not without potential hazards. Patients undergoing RFA may have a variety of side effects, including discomfort, edema, and hypersensitivity near the injection site. These symptoms might emerge as burning sensations or numbness, similar to sunburn, and may last for days or even weeks after the surgery. Such discomfort may cause patient discontent and reluctance to pursue this treatment in the future, affecting overall market acceptance and growth. Furthermore, more significant problems, albeit uncommon, can arise during or following the RFA operation. Infections at the injection site, nerve and blood vessel injury, and bleeding are all possible complications.

Segment Analysis

The global radiofrequency ablation devices market is segmented based on component type, application, end-user, and region.

Capital equipment segment is expected to dominate the global radiofrequency ablation devices market share

The capital equipment segment is anticipated to dominate the global radiofrequency ablation devices market owing to its increasing prevalence of chronic diseases, growing need for effective treatment options, technological advancements, and recent launches and approvals. This expansion relies heavily on capital equipment, which includes expensive goods such as radiofrequency generators and sophisticated ablation devices. These technologies improve both therapy efficacy and patient outcomes, making them indispensable in modern medical procedures. Furthermore, the capital equipment segment benefits from the continuing trend of technological innovation in healthcare. As hospitals and clinics invest in modern RFA systems, they become better prepared to manage complex cases requiring precision and dependability.

Technological advancements in RFA devices have resulted in increased precision and control during operations. Modern RFA systems use modern electrosurgical generators to deliver heat energy more precisely, allowing for targeted tissue destruction while protecting surrounding healthy tissue. These advances not only improve treatment outcomes but also cut recovery times, making RFA a more compelling alternative for patients. There are recent launches and approvals which are manufactured using advanced technology.

For instance, in October 2024, Abbott announced that it has completed two major milestones to support the company's growing suite of pulsed-field ablation (PFA) solutions in electrophysiology, early enrollment in the VOLT-AF IDE Study supporting the Volt PFA System, and the launch of the FOCALFLEX trial to assess the company's TactiFlex Duo Ablation Catheter, Sensor Enabled (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation. These two trials offer major benefits for the future of two Abbott PFA catheters, which are being developed as critical tools for clinicians treating patients with irregular heart rhythms like as atrial fibrillation (AFib).

Geographical Analysis

North America is expected to hold a significant position in the global radiofrequency ablation devices market share

North America will likely account for a significant share of the global radiofrequency ablation devices market, owing to its advanced healthcare infrastructure, increasing investments, a high prevalence of chronic diseases, technological advancements, and recent launches and approvals. This upward trend is primarily attributable to the increasing number of people suffering from chronic ailments such as cancer, arthritis, and cardiovascular disease.

For instance, according to the National Institute of Health, approximately 82.6 million people in the United States suffer from one or more forms of cardiovascular disease (CVD). Coronary heart disease (CHD), stroke, hypertension, and congestive heart failure are among the most common forms of cardiovascular disease. CHD affects an estimated 16.3 million Americans aged 20 and older, accounting for a 7% prevalence. The prevalence for men is 8.3 percent, while for women it is 6.1 percent. About 7 million Americans aged 20 and up have experienced a stroke. Each year, around 610,000 people have their first stroke, with another 185,000 experiencing a recurrence. Approximately 87 percent of all strokes are ischemic, with 10% caused by intracerebral hemorrhage and 3% by subarachnoid hemorrhage. Cardiovascular disease, diabetes, and autoimmune disorders are becoming more prevalent in the population. This frightening trend emphasizes the critical need for improved medical technologies capable of providing appropriate therapies for individuals suffering from chronic diseases.

The development of multi-needle electrodes and enhanced visualization techniques is one of the important technological advances that is driving the market. These advancements give more precision during surgeries, allowing medical professionals to target specific locations more effectively while limiting injury to neighboring tissues. Real-time imaging integration improves the visibility of anatomical features, which is critical for successful therapies. As a result, patients experience better outcomes and shorter recovery times, making RFA a better choice for both physicians and patients.

The market expansion is being driven by increasing expenditures on healthcare and a determined push to adopt modern medical technology, which is critical for tackling the growing prevalence of chronic diseases such as cancer and cardiovascular ailments.

The increased recognition of the benefits of radiofrequency ablation techniques is a major driver of this investment boom. As healthcare providers strive to improve patient outcomes while reducing costs, RFA technology investments have become a top priority. Hospitals and clinics are rapidly spending money to acquire cutting-edge RFA devices with improved precision and safety features. For instance, in June 2024, Kardium, the developer of a pulsed field ablation and mapping system for atrial fibrillation (AFib), announced that it has raised $104 million in the latest fundraising round to assist the firm prepare for commercialization. The funds will be used to finish Kardium's Pulsar clinical study, which is required to secure regulatory approval for their Globe mapping and ablation device. In addition, the company intends to increase its production team and capacity, as well as establish clinical support and commercial teams.

Asia Pacific is growing at the fastest pace in the global radiofrequency ablation devices market

The Asia Pacific region is emerging as the fastest-growing market for radiofrequency ablation devices, owing to a combination of demographic trends, increased healthcare investment, technological advancements, recent launches, and a rising number of chronic diseases. This increase is largely due to the increased prevalence of disorders like as cardiovascular disease (CVDs) and cancer, which require effective treatment alternatives such as RFA.

For instance, according to the National Institute of Health, Coronary heart disease prevalence rates in India have been calculated throughout the last several decades, ranging from 1.6% to 7.4% in rural populations and 1% to 13.2% in metropolitan areas. This disturbing development highlights the critical need for modern medical therapies, such as RFA, to successfully manage these chronic illnesses. The rising prevalence of chronic diseases in Asia Pacific is exacerbated by demographic changes, notably an aging population.

Competitive Landscape

The major global players in the global radiofrequency ablation devices market include Boston Scientific Corporation, Medtronic, Stryke, Abbott, Smith+Nephew, Johnson & Johnson Services, Inc., AngioDynamic, Hologic, Inc., Arthrex, Inc., STARmed America among others.

Emerging Players

Ananya Health, Sedivention, and Field Medical among others

Key Developments

In December 2023, Ajax Health announced the establishment of Cortex, a new company focused on developing comprehensive ablation technology for treating atrial fibrillation (AFib), with an initial funding of $90 million. This investment round was led by prominent firms KKR and Hellman & Friedman, along with contributions from other investors, including AI Life Sciences. The funding will support Cortex's mission to create advanced diagnostic and pulsed-field ablation (PFA) catheters, which are essential for improving treatment outcomes for patients suffering from AFib.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global radiofrequency ablation devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Component Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. Increasing Demand for Radiofrequency Ablation Devices
- 4.1.3. Restraints
- 4.1.4. Side Effects and Complications Associated with Radiofrequency Ablation Devices
- 4.1.5. Opportunity
- 4.1.6. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Component Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 6.1.2. Market Attractiveness Index, By Component Type
6.2. Disposable equipment*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Capital equipment
6.4. Reusable equipment

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Surgical oncology*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cardiology & cardiac rhythm management
7.4. Cosmetology
7.5. Gynecology
7.6. Pain management

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Boston Scientific Corporation*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Medtronic
11.3. Stryker
11.4. Abbott
11.5. Smith+Nephew
11.6. Johnson & Johnson Services, Inc.
11.7. AngioDynamic
11.8. Hologic, Inc.
11.9. Arthrex, Inc.
11.10. STARmed America

LIST NOT EXHAUSTIVE